Finoriq research workspace
ACTUATE THERAPEUTICS, INC. (ACTU) Historical Metrics
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the. Review ACTU valuation ratios, fundamentals, and filing metrics on Finoriq.
Company Snapshot
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as neuroblastoma and pediatric leukemias. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. Actuate Therapeutics, Inc. was incorporated in 2015 and is headquartered in Fort Worth, Texas.
- Company
- ACTUATE THERAPEUTICS, INC. (ACTU)
- Ticker
- ACTU
- Market Cap
- $33.4M
- Latest Price
- $1.395
- Industry
- Biotech & Pharma
ACTUATE THERAPEUTICS, INC. (ACTU) Current Valuation Metrics
Static valuation preview for ACTUATE THERAPEUTICS, INC. (ACTU). Market data retrieved 2026-07-09. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| Earnings YieldLatest TTM net income divided by market cap. | -73.8% | Net Income | TTM Q1 2026 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | -67.2% | Operating Cash Flow | TTM Q1 2026 |
| Price / BookMarket cap divided by stockholders' equity. | 7.71x | Stockholders' Equity | Q1 2026 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.